AR108265A1 - Derivados de feniltriazol sustituidos con amida y usos de estos - Google Patents

Derivados de feniltriazol sustituidos con amida y usos de estos

Info

Publication number
AR108265A1
AR108265A1 ARP170101113A ARP170101113A AR108265A1 AR 108265 A1 AR108265 A1 AR 108265A1 AR P170101113 A ARP170101113 A AR P170101113A AR P170101113 A ARP170101113 A AR P170101113A AR 108265 A1 AR108265 A1 AR 108265A1
Authority
AR
Argentina
Prior art keywords
compounds
feniltriazol
amida
group
formula
Prior art date
Application number
ARP170101113A
Other languages
English (en)
Inventor
Hanna Tinel
Hana Cernecka
Pierre Wasnaire
Heiko Schirmer
Thomas Mondritzki
Karoline Drbner
Anja Buchmller
Klemens Lustig
Matthias Beat Wittwer
Elisabeth Pook
Chantal Frstner
Thomas Neubauer
Peter Kolkhof
Marie Collin
- Kretschmer Axel Pierre
Carsten Schmek
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of AR108265A1 publication Critical patent/AR108265A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/14—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Abstract

La presente se refiere a derivados de 5-(carboxamida)-1-fenil-1,2,4-triazol, a procesos para la preparación de tales compuestos, a composiciones farmacéuticas que contienen tales compuestos, y al uso de tales compuestos o composiciones para el tratamiento y/o prevención de enfermedades, en particular para el tratamiento y/o prevención de enfermedades renales y cardiovasculares. Reivindicación 1: Un compuesto de la fórmula general (1), donde R¹ representa un grupo de la fórmula (2) ó (3), donde #¹ representa el punto de unión al átomo de nitrógeno; Ar representa un grupo de la fórmula (4), donde #² representa el punto de unión al átomo de nitrógeno; R² representa un grupo seleccionado de trifluorometilo, trifluorometoxi, etoxi, -C(=O)N(H)CH₃ y -S(=O)₂CH₃; o una sal, hidrato y/o solvato farmacéuticamente aceptables de esta.
ARP170101113A 2016-05-03 2017-05-02 Derivados de feniltriazol sustituidos con amida y usos de estos AR108265A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16168163 2016-05-03

Publications (1)

Publication Number Publication Date
AR108265A1 true AR108265A1 (es) 2018-08-01

Family

ID=55910849

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP170101111A AR108263A1 (es) 2016-05-03 2017-05-02 Procedimiento para la preparación de derivados de 1-fenilo-1,2,4-triazol sustituidos por 5-hidroxialquilo
ARP170101113A AR108265A1 (es) 2016-05-03 2017-05-02 Derivados de feniltriazol sustituidos con amida y usos de estos

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP170101111A AR108263A1 (es) 2016-05-03 2017-05-02 Procedimiento para la preparación de derivados de 1-fenilo-1,2,4-triazol sustituidos por 5-hidroxialquilo

Country Status (6)

Country Link
US (1) US10815205B2 (es)
EP (1) EP3452470B1 (es)
AR (2) AR108263A1 (es)
TW (1) TW201806943A (es)
UY (1) UY37221A (es)
WO (1) WO2017191107A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210253557A1 (en) 2017-10-24 2021-08-19 Bayer Pharma Aktiengesellschaft Substituted triazole derivatives and uses thereof
PE20210394A1 (es) * 2017-10-24 2021-03-02 Bayer Ag Profarmacos de derivados de triazol sustituido y sus usos
WO2019081291A1 (en) 2017-10-24 2019-05-02 Bayer Aktiengesellschaft PRODRUGS OF SUBSTITUTED TRIAZOLE DERIVATIVES AND USES THEREOF
WO2019081303A1 (en) 2017-10-24 2019-05-02 Bayer Pharma Aktiengesellschaft SUBSTITUTED TRIAZOLE DERIVATIVES AND USES THEREOF
CA3084308A1 (en) 2017-10-24 2019-05-02 Bayer Aktiengesellschaft Substituted triazole derivatives and uses thereof
WO2019081299A1 (en) 2017-10-24 2019-05-02 Bayer Pharma Aktiengesellschaft AMINE SUBSTITUTED TRIAZOLE DERIVATIVES AND USES THEREOF
WO2019081306A1 (en) 2017-10-24 2019-05-02 Bayer Pharma Aktiengesellschaft SUBSTITUTED TRIAZOLE DERIVATIVES AND USES THEREOF
TW201938171A (zh) 2017-12-15 2019-10-01 匈牙利商羅特格登公司 作為血管升壓素Ｖ１ａ受體拮抗劑之三環化合物
HU231206B1 (hu) 2017-12-15 2021-10-28 Richter Gedeon Nyrt. Triazolobenzazepinek
WO2021259852A1 (en) 2020-06-25 2021-12-30 Bayer Aktiengesellschaft Process for preparing 5-(alkoxycarbonyl)-and 5-(carboxamide)-1-aryl-1,2,4-triazole derivatives
WO2022112213A1 (en) 2020-11-30 2022-06-02 Bayer Aktiengesellschaft Crystalline forms of 3-[[3-(4-chlorophenyl)-5-oxo-4-((2s)-3,3,3-trifluoro- 2-hydroxypropyl)-4,5-dihydro-1h-1,2,4-triazol-1-yl]methyl]-1-[3- (trifluoromethyl)pyridin-2-yl]-1h-1,2,4-triazole-5-carboxamide

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3966781A (en) 1970-12-17 1976-06-29 Merck Sharp & Dohme (I.A.) Corporation Deuteration of functional group-containing hydrocarbons
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943634A1 (de) 1999-09-13 2001-04-12 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943636A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943639A1 (de) 1999-09-13 2001-03-15 Bayer Ag Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
DE10110749A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
BRPI0417267A (pt) 2003-12-22 2007-04-17 Pfizer derivados de triazol como antagonistas de vasopressina
BRPI0510340A (pt) 2004-04-28 2007-10-30 Pfizer derivados de 3-heterociclil-4-feniltriazol como inibidores do receptor via da vasopressina
DE102010001064A1 (de) 2009-03-18 2010-09-23 Bayer Schering Pharma Aktiengesellschaft Substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung
RS56312B1 (sr) 2010-02-27 2017-12-29 Bayer Ip Gmbh Ariltriazoloni spojeni sa bis-arilom i njihova upotreba
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
EP2708539A1 (de) 2010-07-09 2014-03-19 Bayer Intellectual Property GmbH Annellierte pyrimidine und triazine und ihre verwendung zur behandlung bzw. prophylaxe von herz-kreislauf-erkrankungen
DE102010040233A1 (de) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclische Aza-Heterocyclen und ihre Verwendung
DE102010043379A1 (de) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung
EP2675440B1 (en) 2011-02-14 2020-03-25 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
MA40893B1 (fr) 2014-11-03 2018-11-30 Bayer Pharma AG Dérivés de phényltriazole à substitution hydroxyalkyle et utilisations associées

Also Published As

Publication number Publication date
UY37221A (es) 2017-11-30
TW201806943A (zh) 2018-03-01
EP3452470A1 (en) 2019-03-13
US10815205B2 (en) 2020-10-27
AR108263A1 (es) 2018-08-01
US20190161454A1 (en) 2019-05-30
WO2017191107A1 (en) 2017-11-09
EP3452470B1 (en) 2020-03-18

Similar Documents

Publication Publication Date Title
AR108265A1 (es) Derivados de feniltriazol sustituidos con amida y usos de estos
AR102487A1 (es) Derivados de feniltriazol sustituido con hidroxialquilo y sus usos
WO2017205536A3 (en) Heterocyclic inhibitors of cbp/ep300 and their use in the treatment of cancer
UY38297A (es) Compuestos derivados de 3-(5-hidroxi-1-oxoisoindolin-2-il)piperidina-2,6-diona, composiciones, métodos y usos de los mismos
CY1119771T1 (el) Ενωσεις αμινοπυριμιδινυλιου ως αναστολεις toy jak
CO2018011933A2 (es) Derivados de piridiniltriazol sustituidos con amida y usos de estos
SG11201809859VA (en) Benzazepine derivative, preparation method, pharmaceutical composition and use thereof
AR107828A1 (es) 2-amino-n-[7-metoxi-2,3-dihidroimidazo-[1,2-c]quinazolin-5-il]pirimidin-5-carboxamidas como inhibidor de pi3k
AR111315A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
JP2016528301A5 (es)
TN2015000445A1 (en) Derivatives of dolastatin 10 and auristatins
NZ767738A (en) Arginase inhibitors and methods of use thereof
PH12018501236A1 (en) Pharmaceutical composition comprising a potent inhibitor urat1
MX2021006544A (es) Inhibidores de cinasa dependiente de ciclina 9 (cdk9) y polimorfos de los mismos para uso como agentes para el tratamiento de cancer.
PH12019500839A1 (en) Therapeutic compounds and methods of use thereof
MX2021011118A (es) Derivados de azolopiridina macrocíclicos como moduladores de eed y prc2.
PH12021550554A1 (en) N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamides useful as ccr6 inhibitors
CO2018006929A2 (es) "compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cáncer"
MX2022003617A (es) Derivados heterociclicos, composiciones farmaceuticas y su uso en el tratamiento o mejora del cancer.
MX2021007258A (es) Composiciones de esparsentan amorfas.
PE20210394A1 (es) Profarmacos de derivados de triazol sustituido y sus usos
BR112018003335A2 (pt) composições farmacêuticas compreendendo 3-(5-amino-2-metil-4-oxo-4h-quinazolina-3-il)-piperidina-2,6-diona
WO2020079184A3 (en) Urea derivatives for treating and/or preventing cancer
MX2020003620A (es) Composiciones y métodos para usar cis-4-[2-{[(3s,4r)-3-fluorooxan- 4-il]amino}-8-(2,4,6-tricloroanilino)-9h-purin-9-il]-1-etilcicloh exano-1-carboxamida.
EA202090241A1 (ru) Новые гетероциклические соединения как ингибиторы cdk8/19

Legal Events

Date Code Title Description
FB Suspension of granting procedure